MEDICINE MOTIVATION:

1. Executive Summary

Date: 29 July 2017

**Medicine (INN):** Betamethasone/ dexamethasone

**Medicine (ATC):** H02AB01/H02AB02

**Indication (ICD10 code):** Fatigue, when treating the underlying cause is not possible or effective (Z51.5)

**Patient population:** Adult palliative care patients

**Prevalence of condition:** Unknown

**Level of Care:** Primary healthcare or hospital level

**Prescriber Level:** Trained palliative care doctor / palliative care teams

**Current standard of Care:** Nil on EDL – new STG

**Efficacy estimates:** (preferably NNT) n/a

**Motivator/reviewer name(s):** Motivator: Dr S.R. Krause. Reviewer: Renee de Waal

**PTC affiliation:** n/a

2. Name of author(s)/motivator(s)

Renee de Waal

3. Author affiliation and conflict of interest details

University of Cape Town

No conflicts of interest

4. Introduction/ Background

Fatigue (defined as a subjective feeling of tiredness, weakness, or lack of energy) in palliative care patients has many disease- or treatment-related causes. Despite limited evidence, corticosteroids (dexamethasone in particular) are widely used to treat fatigue in palliative care patients. The EML PHC ERC received a motivation for betamethasone for this indication from the Palliative Care TWG. The rationale for betamethasone rather than dexamethasone is that oral dexamethasone is available only through section 21 motivation. In contrast, betamethasone, which is considered equivalent to dexamethasone for this indication by palliative care clinicians, is easier to access.

5. Purpose/Objective i.e. PICO question [comparison to current standard of care for a specific indication]:

- **P (patient/population):** Adult palliative care patients
- **I (intervention):** Betamethasone (or dexamethasone)
- **C (comparator):** Placebo, no treatment
- **O (outcome):** 1. Efficacy (improvement in symptoms of fatigue) 2. Adverse effects

(P) Amongst adult palliative care patients with symptoms of fatigue, in whom treatment of the underlying cause is not effective or possible, is (I) betamethasone compared to (C) placebo/no
treatment (O) effective in terms of improvement in fatigue symptoms, with minimal/acceptable side effects?

6. Methods:
   a. Data sources
      Pubmed - searches conducted on 29 July 2017

   b. Search strategy

      Study inclusion criteria:
      Type of studies: RCTs and systematic reviews

      Search terms:
      ("palliative care"[MeSH Terms] OR ("palliative"[All Fields] AND "care"[All Fields]) OR
      "palliative care"[All Fields]) AND ("fatigue"[MeSH Terms] OR "fatigue"[All Fields]) AND
      ("adrenal cortex hormones"[Pharmacological Action] OR "adrenal cortex hormones"[MeSH
      Terms] OR ("adrenal"[All Fields] AND "cortex"[All Fields] AND "hormones"[All Fields]) OR
      "adrenal cortex hormones"[All Fields] OR "corticosteroids"[All Fields])

      Search retrieved 41 articles.

      Substituting the term ‘betamethasone’ for ‘corticosteroids’ retrieved 3 articles – all found in
      the first search. Substituting the term ‘dexamethasone’ for ‘corticosteroids’ retrieved 15
      articles – 2 were additional to the first search: the updated Cochrane Review (described
      below), and another narrative review (excluded). Substituting the terms ‘life threatening
      illness’ or ‘life limiting illness’ for ‘palliative care’ retrieved no articles.

      The search found:
      • no RCTs that involved betamethasone, and 1 that involved dexamethasone(1);
      • 3 systematic reviews (1 in German – could only retrieve English abstract; 1 full text
        not obtainable by committee)(2);
      • 3 uncontrolled prospective or retrospective cohort studies(3-5); and
      • 4 narrative reviews(6-9).
### c. Evidence synthesis

<table>
<thead>
<tr>
<th>Author, date</th>
<th>Type of study</th>
<th>n</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparators</th>
<th>Primary outcome</th>
<th>Effect sizes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucke, 2015</td>
<td>Systematic review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The only relevant study included of dexamethasone was the clinical trial described below. No studies of betamethasone were included.</td>
</tr>
<tr>
<td>Yennurajalingam, 2013</td>
<td>RCT</td>
<td>84</td>
<td>Patients with advanced cancer</td>
<td>Dexamethasone 4 mg 12 hourly for 14 days</td>
<td>Placebo</td>
<td>Change in Functional Assessment of Chronic Illness – Fatigue (FACIT-F) scale at Day 15</td>
<td>Mean (±SD) FACIT-F change from baseline was 9.0 (±10.3) in the dexamethasone group, and 3.1 (±9.6) in the control group (p=0.008).</td>
<td></td>
</tr>
</tbody>
</table>

Several narrative reviews have mentioned that corticosteroids (in general) may be effective in treating fatigue in palliative care patients but most studies quoted did not assess fatigue as a primary endpoint (7). Several observational studies have attempted to identify patients who would benefit most from corticosteroid treatment. However, no clear criteria for treatment have yet been identified.

### d. Evidence quality:

- Very limited evidence – use seems to be guided by expert opinion only.
- No clear evidence for efficacy, or safety.
- No clear evidence regarding dose or duration of treatment, or to list specific indications/contraindications.

### 7. Alternative agents: n/a
<table>
<thead>
<tr>
<th><strong>EVIDENCE TO DECISION FRAMEWORK</strong></th>
<th><strong>SUPPORTING EVIDENCE &amp; ADDITIONAL CONSIDERATIONS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>JUDGEMENT</strong></td>
<td></td>
</tr>
<tr>
<td>What is the overall confidence in the evidence of effectiveness?</td>
<td></td>
</tr>
<tr>
<td>Confident</td>
<td>Not confident</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>BENEFITS &amp; HARMS</strong></td>
<td></td>
</tr>
<tr>
<td>Do the desirable effects outweigh the undesirable effects?</td>
<td></td>
</tr>
<tr>
<td>Benefits outweigh harms</td>
<td>Harms outweigh benefits</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>THERAPEUTIC INTERCHANGE</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic alternatives available:</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>List the members of the group.</td>
<td>Rationale for therapeutic alternatives included:</td>
</tr>
<tr>
<td>List specific exclusion from the group:</td>
<td>References:</td>
</tr>
<tr>
<td>Rationale for exclusion from the group:</td>
<td>References:</td>
</tr>
<tr>
<td><strong>VALUES &amp; PREFERENCES</strong></td>
<td></td>
</tr>
<tr>
<td>Is there important uncertainty or variability about how much people value the options?</td>
<td></td>
</tr>
<tr>
<td>Minor</td>
<td>Major</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Is the option acceptable to key stakeholders?</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
Type of recommendation

- We recommend against the option and for the alternative
- We suggest not to use the option or to use the alternative
- We suggest using either the option or the alternative
- We suggest using the option
- We recommend the option

Recommendation:
Betamethasone is not considered appropriate for prescription at Primary Health Care level at this stage. It could be considered at hospital level, or for prescription by specially trained district palliative care teams (with access at certain PHC facilities via down-referral mechanisms if necessary).

Rationale: Evidence for efficacy is limited, and there are potential risks of adverse effects. Current use is largely based on expert opinion, and is recommended for specific patients only, generally for short-term use, as the benefits appear to be short-lived. Selecting patients for treatment of fatigue, and prescribing betamethasone in this setting, requires palliative care training and experience, which is not currently the norm for PHC facility staff.

Level of Evidence: III Expert opinion

Review indicator:

- Evidence of efficacy: X
- Evidence of harm: 
- Price reduction: 

VEN status:

- Vital: 
- Essential: 
- Necessary: 

Additional resources:
Not feasible for general PHC use. Requires palliative care training.
Monitoring and evaluation considerations

Research priorities

References: